Belviq: A guide to the first FDA-approved obesity drug in 13 years
The Food and Drug Administration tries to shrink America's bulging waistlines by greenlighting a new medication that helps overweight people feel full faster
For the first time in more than a decade, the Food and Drug Administration has approved an anti-obesity drug: Belviq, a new appetite-suppressing pill, was cleared earlier this week (even though the feds initially rejected the drug in 2010 due to safety concerns). Here's what you need to know:
How does it work?
The medicine coaxes the brain into releasing serotonin, a chemical which can suppress appetite by helping people feel full faster, and also appears to give patients a metabolism boost. (Though serotonin is also a key factor in the treatment of depression, Belviq is designed to seek out only those serotonin receptors that affect appetite, says Alice Park at TIME.) Belviq, known generically as lorcaserin, is taken twice a day, and patients are urged to incorporate the drug as part of a healthy diet and exercise program approved by their doctor.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Who should take Belviq?
The FDA approved the drug for obese adults with a body mass index (BMI) of 30 or more, as well as overweight people with a BMI of 27 or more who also have a weight-related health condition, such as Type 2 diabetes or high blood pressure.
How effective is it?
Clinical studies have shown that the drug can lead to "moderate weight loss," says the Associated Press. For example, trial data submitted to the FDA demonstrated that nearly half of all overweight test-subjects with Type 2 diabetes lost at least 5 percent of their starting weight, or an average of 12 pounds over the course of a year. (By contrast, only 23 percent of people taking a placebo lost that much.)
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
What are the side effects?
Potential risks include depression, migraines, and memory lapses. The drug was rejected in 2010 over concerns that it might trigger heart-valve problems, says Park at TIME.
Is the FDA hesitant to approve anti-obesity drugs?
Yes. The last such pill to be approved was Xenical in 1999. And in the past, diet pills have been plagued by safety problems and recalls. A similar serotonin-based drug, fenfluramine, was recalled in 1997, and another weight loss drug, sold as Meridia, was removed from the market in 2010 — in both cases, over fears that the drugs posed cardiological risks.
Then why was Belviq approved?
More than 35 percent of Americans are now considered obese, a three-fold increase from 50 years ago. Belviq was given the green light after its maker convinced the FDA that, at the low doses at which it will be prescribed, Belviq won't cause heart trouble.
Sources: Associated Press, Forbes, Medical News Today, NPR, TIME
Create an account with the same email registered to your subscription to unlock access.
-
Sarah Moss picks her favourite books
The Week Recommends The author shares works by Virginia Woolf, Dorothy Wordsworth and Ross Gay
By The Week UK Published
-
Kamala Harris' 'pragmatic' plan for the economy
The Explainer Tax credits for manufacturing, small businesses, affordable housing
By Joel Mathis, The Week US Published
-
TV to watch in October, from 'Disclaimer' and 'The Franchise'
The Week Recommends An HBO comedy from the 'Veep' creator, a mystery from master filmmaker Alfonso Cuarón and a reboot of an '80s classic
By Anya Jaremko-Greenwold, The Week US Published